[引用][C] Results of the asteroid (assess safety and efficacy of vilaprisan in patients with uterine fibroids) 1 study: a phase 2, placebo-controlled dose finding study
L Bradley, X Ren, E Groettrup-Wolfers, K Petersdorf… - Fertility and …, 2016 - fertstert.org
Objective Selective progesterone receptor modulators (SPRMs) in women with uterine
fibroids (UFs) reduce heavy menstrual bleeding (HMB) and tumor size. We report the results …
fibroids (UFs) reduce heavy menstrual bleeding (HMB) and tumor size. We report the results …
[HTML][HTML] Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study
LD Bradley, SS Singh, J Simon… - Fertility and sterility, 2019 - Elsevier
Objectives To assess the safety and efficacy of four vilaprisan doses (0.5–4.0 mg) in women
with uterine fibroids. Design Randomized, double-blind, placebo-controlled, multicenter trial …
with uterine fibroids. Design Randomized, double-blind, placebo-controlled, multicenter trial …
[HTML][HTML] Rationale and design of ASTEROID 2, a randomized, placebo-and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients …
Abstract Background Uterine fibroids (UFs) may be treated with progesterone receptor
modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the …
modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the …
Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2
K Gemzell-Danielsson, O Heikinheimo, J Zatik… - European Journal of …, 2020 - Elsevier
Objective To assess the efficacy of vilaprisan compared with placebo in the management of
the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive …
the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive …
Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial
A Al-Hendy, YF Zhou, T Faustmann… - F&S Science, 2023 - Elsevier
Objective Vilaprisan is a highly potent selective progesterone receptor modulator shown to
reduce heavy menstrual bleeding, induce amenorrhea, and diminish uterine fibroid volume …
reduce heavy menstrual bleeding, induce amenorrhea, and diminish uterine fibroid volume …
Vilaprisan phase 2B trial: a timely efficacy and safety study of a novel selective progesterone receptor modulator for nonsurgical management of uterine fibroids
JL Magnay - Fertility and Sterility, 2019 - fertstert.org
Uterine fibroids are benign hormone-sensitive tumors of the uterus that often affect women of
reproductive age. Although many fibroids are asymptomatic, some women experience …
reproductive age. Although many fibroids are asymptomatic, some women experience …
[HTML][HTML] Long-term medical management of uterine fibroids with ulipristal acetate
J Donnez, O Donnez, D Matule, HJ Ahrendt… - Fertility and sterility, 2016 - Elsevier
Objective To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg
daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. Design …
daily ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. Design …
Vilaprisan for treating uterine fibroids
GB Melis, M Neri, B Piras, AM Paoletti… - Expert opinion on …, 2018 - Taylor & Francis
Introduction: The medical strategy to antagonize myoma size and related-symptoms is to
reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH …
reduce estrogen and progesterone activity on myomas. This can be obtained with the GnRH …
Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough?
M Ciebiera, SG Vitale, S Ferrero… - Current …, 2020 - ingentaconnect.com
Background: Vilaprisan (VPR) is a new orally available selective progesterone receptor
modulator (SPRM), with anti-proliferative activity against uterine fibroids (UFs). It definitively …
modulator (SPRM), with anti-proliferative activity against uterine fibroids (UFs). It definitively …
[HTML][HTML] Safety after extended repeated use of ulipristal acetate for uterine fibroids
BCJM Fauser, J Donnez, P Bouchard, DH Barlow… - PLoS …, 2017 - journals.plos.org
Objective To assess long term safety of extended repeated 3-month courses of ulipristal
acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory …
acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory …
相关搜索
- patients with uterine fibroids
- uterine fibroids dose finding
- uterine fibroids vilaprisan in women
- uterine fibroids ulipristal acetate
- uterine fibroids randomized placebo
- uterine fibroids randomized phase
- nonsurgical management of uterine fibroids
- uterine fibroids medical management
- safety and efficacy dose finding
- uterine fibroids safety of vilaprisan
- efficacy and safety vilaprisan in women
- efficacy and safety randomized placebo
- randomized phase vilaprisan in women
- safety of vilaprisan randomized placebo